Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Molecular Monitoring afte… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years

Artikel i vetenskaplig tidskrift
Författare Arne Kolstad
Lone Bredo Pedersen
Christian W. Eskelund
Simon Husby
Kirsten Grønbæk
Mats Jerkeman
Anna Laurell
Riikka Räty
Erkki Elonen
Niels Smedegaard Andersen
Peter de Nully Brown
Eva Kimby
Hans Bentzen
Christer Sundström
Mats Ehinger
Marja Liisa Karjalainen-Lindsberg
Jan Delabie
Elisabeth Ralfkiær
Unn Merete Fagerli
Herman Nilsson-Ehle
Grete Fossum Lauritzsen
Outi Kuittinen
Carsten Niemann
Christian Hartman Geisler
Publicerad i Biology of Blood and Marrow Transplantation
Volym 23
Nummer/häfte 3
Sidor 428-435
ISSN 10838791
Publiceringsår 2017
Publicerad vid
Sidor 428-435
Språk en
Länkar dx.doi.org/10.1016/j.bbmt.2016.12.6...
Ämnesord Autologous stem cell transplantation, Mantle cell lymphoma, Minimal residual disease, Preemptive rituximab
Ämneskategorier Hematologi

Sammanfattning

© 2017 The American Society for Blood and Marrow Transplantation The main objectives of the present study were to monitor minimal residual disease (MRD) in the bone marrow of patients with mantle cell lymphoma (MCL) to predict clinical relapse and guide preemptive treatment with rituximab. Among the patients enrolled in 2 prospective trials by the Nordic Lymphoma Group, 183 who had completed autologous stem cell transplantation (ASCT) and in whom an MRD marker had been obtained were included in our analysis. Fresh samples of bone marrow were analyzed for MRD by a combined standard nested and quantitative real-time PCR assay for Bcl-1/immunoglobulin heavy chain gene (IgH) and clonal IgH rearrangements. Significantly shorter progression-free survival (PFS) and overall survival (OS) was demonstrated for patients who were MRD positive pre-ASCT (54 patients) or in the first analysis post-ASCT (23 patients). The median PFS was only 20 months in those who were MRD-positive in the first sample post-ASCT, compared with 142 months in the MRD-negative group (P  <  .0001). OS was 75% at 10 years and median not reached in the MRD-negative group, compared with only 35 months in the MRD-positive group (P  <  .0001). Of the 86 patients (47%) who remained in continuous molecular remission, 73% were still in clinical remission after 10 years. For all patients, the median time from ASCT to first molecular relapse was 55 months, with a continuous occurrence of late molecular relapses. Fifty-eight patients who experienced MRD relapse received rituximab as preemptive treatment on 1 or more occasions, and in this group, the median time from first molecular relapse to clinical relapse was 55 months. In most cases, rituximab converted patients to MRD negativity (87%), but many patients became MRD-positive again later during follow-up (69%). By multivariate analysis, high-risk Mantle Cell Lymphoma International Prognostic Index score and positive MRD status pre-ASCT predicted early molecular relapse. In conclusion, preemptive rituximab treatment converts patients to MRD negativity and likely postpones clinical relapse. Molecular monitoring offers an opportunity to select some patients for therapeutic intervention and to avoid unnecessary treatment in others. MRD-positive patients in the first analysis post-ASCT have a dismal prognosis and thus are in need of novel strategies.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?